SCHEMBL6802285

SCHEMBL6802285

COC(=O)[C@@H](N(C)C(=O)OC(C)(C)C)C(C)(C)c1ccc(C=O)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
ADRB3 P13945 1/20 0.35
EPHX2 P34913 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
KDM4E B2RXH2 2/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
MAPT P10636 1/20 0.32
AAK1 Q2M2I8 2/20 0.31
MMP13 P45452 1/20 0.31
CYP2A6 P11509 2/20 0.31
CYP2A13 Q16696 1/20 0.31
MIF P14174 1/20 0.31
RECQL P46063 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
NOS3 P29474 1/20 0.30
NOS1 P29475 1/20 0.30
NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6804595 0.89 TAS1R3 (0.39) KDM4EAAK1MMP13MIF
SCHEMBL16176663 0.85 AAK1 (0.41) ALDH1A1NPC1RAB9AMAPTAAK1
SCHEMBL6805608 0.85 AAK1 (0.41) ALDH1A1NPC1RAB9AMAPTAAK1
SCHEMBL88675 0.84 MMP13 (0.40) RAB9AAAK1MMP13
SCHEMBL57636 0.84 MMP13 (0.40) RAB9AAAK1MMP13
SCHEMBL16176767 0.84 CHRNB2 (0.40) ADRB2ADRB1ADRB3EPHX2POLB
SCHEMBL16176766 0.84 CHRNB2 (0.40) ADRB2ADRB1ADRB3EPHX2POLB
SCHEMBL6810467 0.84 NOTUM (0.38) MAPTAAK1MMP13
SCHEMBL7066900 0.84 SRD5A2 (0.38) EPHX2NR1H4MAPTMMP13SMN1; SMN2
SCHEMBL16183161 0.82 L3MBTL1 (0.39) ALDH1A1AAK1MMP13SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040121965-A1 Method of treating resistant tumors WYETH HOLDINGS CORPORATION (US) 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121965-A1 Method of treating resistant tumors SLC11A2, VHL, REN ALDH1A1 612/4885ADRB2 1273/4885ADRB1 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.